Skip to main content

Aveo Pharmaceuticals, Inc.

AVEODelisted Jan 19, 2023
Industry
Pharmaceutical Preparations
SEC CIK
0001325879

Aveo Pharmaceuticals, Inc. was delisted on Jan 19, 2023; its insiders filed their last Form 4 on Jan 19, 2023; 110 institutions reported holding it in 13F filings for Q4 2022, worth $367.6M in total; no superinvestor held it.

Q3 2021 vs. Q2 2021

How the institutions holding Aveo Pharmaceuticals, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of AVEO: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders6251−11
Shares14.3M15.0M+714.6K (+5.0%)
Value$94.2M$92.7M−$1.45M (−1.5%)

New holders (12)

Institutions that held Aveo Pharmaceuticals, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to AVEO in Q3 2021
InstitutionSharesValue% of portfolio
AIGH Capital Management LLC1,986,176$12.3M3.64%
Worth Venture Partners, LLC454,364$2.81M1.27%
Brandywine Global Investment Management, LLC129,500$800.0K0.01%
Citadel Advisors LLC47,855$295.0K0.00%
Birchview Capital, LP40,000$247.0K0.17%
Gsa Capital Partners LLP35,232$218.0K0.02%
Cubist Systematic Strategies, LLC33,548$207.0K0.00%
Grimes & Company, Inc.21,640$134.0K0.01%
Charles Schwab Investment Management Inc17,180$107.0K0.00%
Connor, Clark & Lunn Investment Management Ltd.14,742$91.0K0.00%
Virtu Financial LLC10,342$64.0K0.01%
Golden State Wealth Management, LLC500$3.00K0.00%

Sold out (23)

Institutions that held Aveo Pharmaceuticals, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.